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In this study we compared the response of the Pig-a
gene mutation assay to that of the lacZ transgenic
rodent mutation assay, and demonstrated that multi-
ple endpoints can be measured in a 28-day repeat
dose study. Muta
TMMouse were dosed daily for 28
days with benzo[a]pyrene (BaP; 0, 25, 50 and 75
mg/kg body weight/day) by oral gavage. Micro-
nucleus (MN) frequency was determined in reticulo-
cytes (RETs) 48 hr following the last dose. 72 h fol-
lowing the last dose, mice were euthanized, and
tissues (glandular stomach, small intestine, bone
marrow and liver) were collected for lacZ mutation
and DNA adduct analysis, and blood was eval-
uated for Pig-a mutants. BaP-derived DNA adducts
were detected in all tissues examined and signiﬁ-
cant dose-dependent increases in mutant Pig-a phe-
notypes (i.e., RET
CD24- and RBC
CD24-)a n dlacZ
mutants were observed. We estimate that muta-
genic efﬁciency (i.e., rate of conversion of adducts
into mutations) was much lower for Pig-a compared
to lacZ, and speculate that this difference is likely
explained by differences in repair capacity
between the gene targets, and differences in the
cell populations sampled for Pig-a versus lacZ.T h e
BaP doubling doses for both gene targets, how-
ever, were comparable, suggesting that similar
mechanisms are involved in the accumulation of
gene mutations. Signiﬁcant dose-related increases
in % MN were also observed; however, the dou-
bling dose was considerably higher for this end-
point. The similarity in dose response kinetics of
Pig-a and lacZ provides further evidence for the
mutational origin of glycosylphosphatidylinositol
(GPI)-anchor deﬁciencies detected in the Pig-a
assay. Environ. Mol. Mutagen. 52:756–765,
2011. V V C 2011 Wiley Periodicals, Inc.
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INTRODUCTION
Data for the induction of gene mutations in vivo form an
increasingly important component of hazard and risk assess-
ment. One widely used and well-validated system for
assessment of gene mutations in vivo is the transgenic
rodent (TGR) mutation assay system (for review see
[Lambert et al., 2005; OECD, 2009]). Commonly used
versions of the TGR assays include the lacZ bacteriophage
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TMMouse [Gossen et al., 1989; Vijg and
Douglas 1996], the lacI or BigBlue
TM rodents (rat and
mouse), the lacZ plasmid mouse, and the gpt-delta mouse
[Lambert et al., 2005]. The regulatory importance of these
assays has been recognized by the Organization for Eco-
nomic Cooperation and Development (OECD) and an
OECD Test Guideline (no. 488) was approved in 2011
[OECD, 2011].
Another promising assay for in vivo gene mutation test-
ing is the recently developed Pig-a mutation assay. The
Pig-a assay has multispecies capability and, when fully
validated, may constitute an effective tool for in vivo
mutation research and hazard assessment [Bryce et al.,
2008; Phonethepswath et al., 2008; Dobrovolsky et al.,
2010]. The Pig-a assay is based on detection of glycosyl-
phosphatidylinositol (GPI) anchored proteins on the cell
surface of circulating blood cells (reticulocytes or RETs)
and red blood cells (RBCs). The Pig-a (phosphatidylinosi-
tol glycan complementation group A) gene product is
involved in the ﬁrst step of GPI anchor biosynthesis, and
since it is the only X-linked gene involved in the GPI
anchor synthesis pathway, it is generally accepted that a
single mutation at the Pig-a locus can prevent the anchor-
ing of GPI anchored proteins (i.e., CD24 in mouse, or
CD59 in rat). Mutant RBCs or RETs therefore lack cell
surface expression of these proteins (RBC
CD242 or
RET
CD242), and this phenotype can readily be detected
by ﬂow cytometry. For a detailed description of the assay,
the reader is referred to [Phonethepswath et al., 2008].
Several research groups have been working towards the
validation of this assay (for example see [Miura et al.,
2008; Phonethepswath et al., 2010; Kimoto et al., 2011])
and it is the focus of this Special Issue; however, much
work still remains to be completed before the assay can
be routinely used for regulatory genetic toxicity testing.
This study contributes to the validation of the Pig-a
endpoint by comparing its responsiveness to that of the
well established lacZ TGR mutation assay for the well-
known mutagenic carcinogen benzo[a]pyrene (BaP). The
results of this study provide useful information on how
induction of mutant Pig-a phenotypes compares to that of
a well established and validated mutation target, (i.e.,
lacZ), in the same animals.
An important feature of this study is the integration of
multiple genotoxicity endpoints in a single experiment.
This facilitates reduction of the number of animals used
for testing, as recommended by the European Centre for
the Validation of Alternative Methods (ECVAM) [Pfuhler
et al., 2009]. Although there has been progress in the inte-
gration of multiple endpoints into 28-day repeat dose
studies (for example, see [Dertinger et al., 2010; Shutsky
et al., 2010]), further work is required in order to deter-
mine the most appropriate endpoints, dosing regimes, and
sampling times.
This study has three overall objectives: (1) to contribute
to the validation of the Pig-a assay by comparing the
response of the Pig-a assay to the well established lacZ
mutation assay; (2) to assess how simultaneous measure-
ment of multiple endpoints (for mutation, chromosome
damage and DNA adducts) can be achieved in a single
28-day subchronic mouse study; and (3) to determine the
utility of DNA adduct data in assessing the efﬁciency of
mutation induction. We hypothesized that, although the
two mutation assays examine different loci (i.e., Pig-a
and lacZ), their responses would be similar given their
presumed similar mechanisms of action. Conversely, we
expected that the dose-response kinetics of BaP-induced
micronucleus formation would be different, given that this
cytogenetic damage endpoint is sensitive to different
types of lesions.
MATERIALS ANDMETHODS
Chemicals
All chemicals were obtained from Sigma Aldrich Canada (Oakville,
ON), except Tris-HCl, phosphate buffered saline (PBS), and proteinase-
K, which were obtained from Invitrogen Canada (Burlington, ON).
AnimalTreatment
Twenty-ﬁve-week old male Muta
TMMouse specimens (i.e., transgenic
mouse strain 40.6) were dosed daily via oral gavage for 28 days with
BaP dissolved in olive oil (25, 50, and 75 mg/kg body weight/day). Each
dose group, including vehicle control, contained ﬁve animals. Following
OECD Test Guideline 474 [OECD, 1997], peripheral blood for MN anal-
ysis was collected from the saphenous vein 48 hr after the last treatment.
Following a three-day sampling period after the ﬁnal treatment, mice
were anaesthetized with isoﬂuorane to permit blood collection via car-
diac puncture. This was immediately followed by cervical dislocation.
60 ll aliquots of the collected blood were processed for the Pig-a muta-
tion endpoint analysis. Tissues, including liver, bone marrow, small
intestine, and glandular stomach, were isolated, ﬂash-frozen in liquid
nitrogen, and stored at 2808C until use. One mouse, dosed i.p. with eth-
ylnitrosourea (45 mg/kg body weight) two weeks prior to necrospsy was
used as a positive control for the Pig-a assay. Mice were maintained
under conditions approved by the Health Canada Animal Care Commit-
tee. Food and water were available ad libitum for the duration of the
experiment.
Genomic DNAIsolation
GlandularStomach
Mucosal cells from glandular stomach were isolated and lysed accord-
ing to [Brault et al., 1999]. Brieﬂy, glandular stomach was thawed, and
stomach mucosal cells were removed from the inner lining of the glan-
dular stomach, and were homogenized in 5 ml lysis buffer (1 mM
Na2EDTA, 100 mM NaCl, 20 mM Tris-HCl, pH 7.4), supplemented
with 1% SDS (w/v) and 0.1 mg/ml Rnase A and incubated for 1 hr at
378C. Proteinsase K (1 mg/ml) was added and cells were incubated at
378C overnight with gentle shaking. Genomic DNA was isolated the day
following lysis, using the phenol/chloroform extraction procedure
described previously [Douglas et al., 1994; Vijg and Douglas 1996].
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1 mM EDTA) and stored at 48C until used.
Bone marrow
To collect bone marrow, femurs were ﬂushed with PBS, the solution
was brieﬂy centrifuged, and the pellet was stored at –808C. DNA was
extracted as described above.
Small intestine
Epithelial cells were isolated from the jejunum of the small intestine
using a method modiﬁed from [Tao et al., 1993] and [Trentin et al.,
1998]. Frozen tissue was defrosted on ice and slit open in 1.5 ml cold
‘‘snapping buffer" (75 mM KCl, 20 mM EDTA). The tissue was passed
quickly into and out of a 1-ml syringe (i.e., ‘‘snapped") three times, and
the buffer was discarded. The tissue was then snapped six to nine times
in an additional 3 ml of buffer before the cell suspension was collected
and centrifuged for 10 min at 1,500 g and 48C. DNA was extracted from
the cell pellet as described above.
Liver
Liver tissue was thawed and homogenized on ice using a motor-driven
conical tissue homogenizer in 7 ml TMST buffer (50 mM Tris pH 7.6, 3
mM magnesium acetate, 250 mM sucrose, 0.2% (v/v) Triton X-100).
The liver homogenate was centrifuged for 6 min at 800 g (48C), the su-
pernatant was discarded, and the pellet was washed twice more with
TMST buffer as before. The pellet was suspended in 5 ml lysis buffer
(10 mM Tris pH 7.6, 10 mM EDTA, 150 mM NaCl, 1% (w/v) SDS and
1mg/ml proteinase K ( 20 Units/mg). This suspension was incubated
overnight at 378C. Again, DNA was extracted as described above.
DNA Adduct Analysis
DNA adducts were measured in bone marrow, liver, glandular stomach,
and small intestine using the
32P-postlabeling method with nuclease P1
digestion enrichment [Phillips and Arlt, 2007]. All enzymes and chemicals
used for this assay were purchased from sources previously described in
[Phillips and Arlt, 2007]. Brieﬂy, DNA samples (4 lg) were digested with
micrococcal nuclease (120 mUnits) and calf spleen phosphodiesterase (40
mUnits), enriched and labeled as reported elsewhere [Philips and Arlt,
2007]. Chromatographic conditions for thin-layer chromatography (TLC)
on polyethyleneimine-cellulose (PEI-cellulose) plates (Macherey-Nagel,
Du ¨ren, Germany) were [Arlt et al., 2008]: D1, 1.0 M sodium phosphate,
pH 6; D3, 4 M lithium-formate, 7 M urea, pH 3.5; D4, 0.8 M LiCl, 0.5
M Tris, 8.5 M urea, pH 8. After chromatography, TLC sheets were
scanned using a Packard Instant Imager (Dowers Grove, IL) and DNA
adduct levels (RAL, relative adduct labeling) were calculated from adduct
cpm, the speciﬁc activity of [g-
32P]ATP and the amount of DNA (pmol
of DNA-P) used. An external BaP-diol-epoxide-DNA standard was used
for identiﬁcation of BaP-DNA adducts [Phillips and Castegnaro 1999].
Results are expressed as DNA adducts/10
8 nucleotides.
EvaluationofMutantPig-a Phenotypes
RBCs were enriched by centrifugation with Lympholyte
1 and then
washed with PBS. These coded specimens were shipped overnight on ice
packs to Litron Laboratories for ﬂow cytometric analysis. Enriched
RBCs were incubated with anti-mouse-CD24-PE, washed, and then incu-
bated with the cell permeable nucleic acid dye SYTO 13 as described in
Phonethepswath et al. [2008]. For each specimen, the frequency of RETs
and mutant phenotype RBCs was measured by interrogating approxi-
mately 10
6 RBCs. The frequency of mutant phenotype RETs was meas-
ured by interrogating at least 3 3 10
5 RETs per specimen using ﬂow
cytometry.
lacZMutationEvaluation
The frequency of lacZ transgene mutants in genomic DNA isolated
from liver, bone marrow, glandular stomach and small intestine was
measured using the P-Gal positive selection assay as previously
described [Vijg and Douglas, 1996; Lambert et al., 2005]. kgt10lacZ
DNA was rescued from genomic DNA using the Transpack
TM lambda
packaging system (Agilent, Mississauga, ON). Packaged phage particles
were then mixed with the host bacterium (Escherichia coli lacZ
2, galE
2,
recA
2, pAA119 with galT and galK) [Gossen et al., 1992], plated on
minimal medium containing 0.3% (w/v) P-Gal and incubated overnight
at 378C. Total plaque-forming units (pfu) were measured on concurrent
titre plates that did not contain P-Gal. Mutant frequency (MF) is
expressed as the ratio of mutant pfu to total pfu.
MicronucleusEvaluation
For evaluation of micronuclei, blood samples ( 100 ll) were col-
lected from the saphenous vein 48 hr following the last treatment
[OECD, 1997], and ﬁxed according to MicroFlow
1 kit instructions.
Coded specimens were shipped to Litron Laboratories for analysis,
where they were stained and analyzed using a 3-color labeling method
described by Dertinger et al. [2004]. Instrument settings were optimized
with a MicroFlow-kit supplied biological standard (i.e., malaria-infected
erythrocytes; Tometsko et al., 1993). The frequencies (%) of RETs,
micronucleated RETs (MN-RET) and micronucleated NCEs (MN-NCE)
were determined upon the acquisition of  20,000 RETs per specimen.
StatisticalAnalyses
All data (i.e., adduct level, lacZ mutant frequency, mutant Pig-a phe-
notype frequency, and micronucleus frequency data) were analyzed by
Poisson Regression using SAS v.9.1 (SAS Institute, Cary, NC). The data
were ﬁt to the model log(E(Yi)) 5 log ti 1  ixi, where E(Yi) is the
expected value for the ith observation,  i is the vector of regressions coef-
ﬁcients, xi is a vector of covariates for the ith observation, and ti is the
offset variable used to account for differences in observation count pe-
riod (i.e., total pfu or total RETs). The offset (i.e., natural log) was given
a constant coefﬁcient of 1.0 for each observation, and log-linear relation-
ships between mutant count and test article concentration were speciﬁed
by a natural log link function. Type 1, or sequential analysis, was
employed to examine the statistical signiﬁcance of the BaP treatment,
and custom contrasts were employed to evaluate the statistical signiﬁ-
cance of responses at each dose tested.
BaP doubling dose (i.e., the dose of BaP required to elicit a doubling
in the spontaneous frequency) was calculated for each of the endpoints
according to the method of Dubrova [2005], Eq. (1).
Doubling dose ¼ ls=mi ð1Þ
where ls is the spontaneous frequency, and mi is the slope of the dose-
response function.
The slopes of the dose-response functions, or mi, were calculated
using ordinary least squares regression. Standard deviation for each dou-
bling dose was calculated according to Sankaranarayanan and Chakra-
borty [2000]. The two-tailed Student’s t test (p < 0.05), with the appro-
priate multiple test correction (i.e., Bonferroni correction), was used to
compare doubling doses across endpoints.
RESULTS
Transgenic mice were exposed to BaP daily for 28
days via oral gavage, and simultaneous measurements of
DNA adduct frequency, micronucleus frequency, lacZ
Environmental and Molecular Mutagenesis. DOI 10.1002/em
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notypes were carried out in an effort to better understand
the responsiveness of Pig-a phenotype frequency relative
to other established genotoxicity endpoints for the proto-
typical polycyclic aromatic hydrocarbon BaP. No overt
signs of toxicity were observed in any dose group, includ-
ing controls, and no statistically signiﬁcant reductions in
body weight were observed.
DNA Adducts
DNA adducts were evaluated three days following the
last treatment, via
32P postlabeling analysis, as a measure
of internal dose of the active BaP metabolite to target tis-
sues. Using an external BaP-diol-epoxide-DNA standard,
the main adduct detected was identiﬁed as dG-N
2-BPDE
(BaP-7,8-diol-9,10-epoxide-N
2-deoxyguanosine). DNA adducts
were found to be present in all four of the tissues exam-
ined (Fig. 1), and all doses yielded DNA adduct levels that
were signiﬁcantly elevated compared to control (p < 0.05)
in all tissues, with the exception of the low dose group (25
mg/kg body weight/day) in glandular stomach. Further-
more, DNA adduct formation was dose-dependent (dose
effect p < 0.005). No DNA adducts were observed in the
control animals.
Mutagenic Response toBaP
Evaluation ofMutantPig-aPhenotypes
The frequency of mutant Pig-a phenotypes was measured
using ﬂow cytometry for RBCs and RETs in blood samples
obtained at necropsy (i.e., 72 hr following the last dose).
Figure 2 summarizes the mutagenic response observed for
the Pig-a locus. Dose-dependent increases in mutant pheno-
type RETs and RBCs (i.e., RET
CD242 and RBC
CD242)
were observed in both cell populations (for RET
CD242
Poisson regression chi-square for test article concentration
effect 5 129.10, p < 0.0001, and for RBC
CD242 Poisson
regression chi-square for test article concentration effect
583.82, p < 0.0001). Moreover, a higher proportion of mu-
tant cells were consistently observed in the RET cohort
compared to the RBC cohort; however, in both cell popula-
tions, each dose group was signiﬁcantly elevated compared
to control (p < 0.05). One mouse, treated with a single i.p.
dose of ENU (45 mg/kg body weight) was used as a posi-
tive control, and it also showed an increased frequency of
RET
CD242 and RBC
CD242. There also appeared to be a
slight increase in % RETs with increasing BaP dose. This
effect has also been observed in BaP-treated rats [Bhalli
et al., 2011b], although it should be noted that BaP itself
endows RBCs with a modest amount of green ﬂuorescence,
and this may have interfered with ﬂow cytometric quantiﬁ-
cation of % RETs.
lacZMutationEvaluation
MF for the lacZ transgene was evaluated in four tissues
(liver, bone marrow, glandular stomach, and small intes-
tine) 72 hr following the last dose. Figure 3 summarizes
the mutagenic response at the lacZ transgene. A dose-de-
pendent increase in BaP-induced lacZ MF was observed
in all four tissues (Poisson regression chi-square for test
article concentration effect 5 149.56 for bone marrow,
237.95 for liver, 156.95 for small intestine and 179.09 for
glandular stomach, p < 0.0001 for all tissues.) Small
intestine consistently yielded the highest frequency of
lacZ mutants, followed by bone marrow, glandular stom-
ach, and liver. In all tissues, all doses of BaP yielded a
frequency of lacZ mutants that was signiﬁcantly elevated
Environmental and Molecular Mutagenesis. DOI 10.1002/em
Fig. 1. Relative adduct labeling (DNA adducts per 10
8 nucleotides) of
BaP-7,8-diol-9,10-epoxide-N
2-deoxyguanosine (BPDE) adducts in tissues
of BaP-treated Muta
TM Mouse. Values are means of measurements from
ﬁve separate animals (each DNA sample analysed in two independent
postlabeling assays), and error bars represent standard error of the mean.
(* indicates p < 0.05 compared to control).
Fig. 2. Frequency of mutant Pig-a phenotypes observed in reticulocytes
(RETs) and red blood cells (RBCs). Bars represent the mean of measure-
ment from ﬁve separate animals and error bars represent the standard
error of the mean. The positive control represents the response observed
for one mouse treated with 45 mg/kg body weight ethylnitrosourea (i.p.)
two weeks prior to necropsy. (* indicates p < 0.05 compared to control)
Note that no mutant phenotype RETs were observed in control animals,
while in RBC, 0.40 3 10
26 6 0.25 3 10
26 mutant phenotypes were
observed.
Benzo[a]pyrene-inducedPig-a andlacZMutations 759compared to control (p < 0.005). Spontaneous MF
(310
25) for each of the tissues are as follows (standard
error in brackets): liver: 6.31 (1.30), bone marrow: 3.97
(1.39) and glandular stomach: 5.95 (2.71), small intestine:
32.77 (30.36).
MicronucleusFormation
We also measured micronucleus frequency in blood
from BaP-exposed animals collected 48 hr following the
last treatment. Figure 4 summarizes these results. A dose-
dependent increase in % MN-RETs and % MN-NCE was
observed (for RETs, Poisson regression chi-square for test
article concentration effect 5 46.77, p < 0.0001, and for
NCEs, Poisson regression chi-square for test article concen-
tration effect 5 112.53, p < 0.0001). In both cell popula-
tions, each dose group was signiﬁcantly elevated compared
to control (p < 0.05). A dose-dependent increase in %
RET was also observed conﬁrming target tissue exposure.
ComparisonofResponses acrossEndpoints
An important component of the validation of the Pig-a
assay is the comparison of the responsiveness of the mu-
tant Pig-a phenotype endpoint to that of a well-estab-
lished in vivo gene mutation assay. In this study, we com-
pared the induction of BaP-induced mutant Pig-a pheno-
types (as RET
CD242) to the induction of lacZ mutants in
the bone marrow, in the same animals. As depicted in
Figure 5 the dose-response relationships observed for
Pig-a (i.e., RET
CD242) and lacZ MF in bone marrow, are
similar. Linear regression analysis of lacZ MF versus the
frequency of RET
CD242 cells at matched BaP doses
revealed a strong correlation (r
2 5 0.94, p < 0.05). Inter-
estingly, the maximum lacZ MF in bone marrow was
approximately 25-fold higher than the frequency of phe-
notypic mutants observed for Pig-a in RETs.
The BaP doubling dose (i.e., the dose of BaP required
to elicit a doubling in the spontaneous frequency) for
each of the endpoints measured in this study was calcu-
lated to permit a quantitative comparison of response
induction across endpoints (Table I). Unlike other
response metrics (e.g., mutation frequency), doubling dose
permits comparison across endpoints and loci, regardless
of the response unit. The BaP doubling doses for lacZ
MF in all four tissues appear to be correlated with tissue-
speciﬁc cell turnover rates, with relatively quiescent tis-
sues such a liver showing higher doubling doses. Only the
doubling doses calculated for liver and bone marrow are
signiﬁcantly different from each other (p < 0.05). More-
over, the doubling dose for RET
CD242 and RBC
CD242 are
not signiﬁcantly different from the lacZ doubling dose in
bone marrow. However, the doubling dose for micronu-
cleus formation is an order of magnitude higher than that
calculated for the gene mutation endpoints (lacZ or
Pig-a), and signiﬁcantly different (p < 0.05).
Mutagenic efﬁciency, indicative of the rate of conver-
sion of DNA adducts into mutations (expressed as number
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Fig. 3. Frequency of lacZ mutants observed in liver, bone marrow,
glandular stomach and small intestine of BaP-exposed Muta
TM Mouse.
Bars represent the mean of measurement from ﬁve separate animals and
error bars represent the standard error of the mean. (* indicates p < 0.05
compared to control).
Fig. 4. Frequency of micronucleated reticulocytes (% MN-RET) and
micronucleated normochromatic erythrocytes (% MN-NCE) in BaP-
exposed Muta
TM Mouse. Bars represent the mean of measurement from
ﬁve separate animals and error bars represent the standard error of the
mean. (
*denotes p < 0.005 compared with control).
Fig. 5. Dose-response relationship for BaP-induced mutants at the lacZ
transgene in bone marrow and the frequency of mutant Pig-a phenotypes in
reticulocytes (RETs). Note the difference in scale between the two y-axes.
760 Lemieuxet al.of mutants per DNA adduct in 10
8 nucleotides at a given
dose), was calculated for lacZ mutants in bone marrow
and mutant Pig-a phenotypes in RETs. The mutagenic ef-
ﬁciency of lacZ in bone marrow was found to be 25-fold
higher than that for RET
CD242 (Table II). However, it is
important to note that since it was not possible to measure
DNA adducts directly in the RET population, we have
estimated the mutagenic efﬁciency at the Pig-a locus
based on the level of DNA adducts in the entire bone
marrow. Accordingly, the mutagenic efﬁciency for Pig-a
could not be adjusted for the proportion of bone marrow
DNA adducts in RET or RBC progenitor cells.
DISCUSSION
In this study we have carried out a subchronic, 28-day
BaP exposure in Muta
TMMouse in an effort to compare
the response of mutant Pig-a phenotype formation with
that of mutation formation in the well-studied lacZ trans-
gene. We have shown that these mutational endpoints,
along with measurements of internal dose (i.e., DNA
adducts) and chromosomal damage (i.e., micronucleus
formation), can be effectively integrated into a 28-day
repeat dosing study, thus reducing the number of animals
required in subchronic genotoxicity studies.
The presence of DNA adducts in these animals shows
that BaP was converted to its active metabolite (i.e.,
BPDE) and delivered to target tissues. The relative levels
of adducts observed across tissues is not surprising (liver
> glandular stomach > small intestine > bone marrow),
given the route of exposure (i.e., oral gavage) and phar-
macokinetic factors at play. In this study, the primary site
of contact for BaP is the stomach, followed by the small
intestine. BaP is then carried to the liver, the primary site
of systemic metabolism, via hepatic portal circulation.
BaP and its metabolites must enter systemic circulation in
order to reach the bone marrow. Accordingly, the levels
of DNA adducts are highest in glandular stomach and
liver, the sites of contact and primary site of metabolism,
respectively, and lowest in the bone marrow and small
intestine (Fig. 1). Differences in the levels of metaboliz-
ing enzymes (e.g., P450) are also known to vary between
tissues, and may account for some of the differences
observed in DNA adduct levels.
Dose-dependent increases in both mutant Pig-a pheno-
types (in RETs and RBCs) and lacZ mutants (in bone
marrow, liver, glandular stomach and small intestine)
were observed. The rate of conversion of DNA adducts
into mutations, estimated using the ratio of mutant fre-
quency to adduct frequency, and denoted as mutagenic ef-
ﬁciency, was calculated for both of these mutation targets
in order to compare susceptibility of the two loci. We
estimate that the efﬁciency of converting BaP-DNA
adducts in the bone marrow into lacZ mutants is 25-fold
higher than for mutant Pig-a phenotypes in RETs. Simi-
larly, the magnitude of the lacZ response in bone marrow
is approximately 25-fold higher than the Pig-a response
in RETs, suggesting that the rate of conversion of adducts
is slower for the Pig-a endpoint compared with the lacZ
endpoint. In contrast, the BaP doubling dose for the lacZ
mutation endpoint in bone marrow is not signiﬁcantly dif-
ferent from the the Pig-a endpoint (in both RETs and
RBCs) (Table I). Taken together, these results suggest
that, although the rate of conversion of adducts into muta-
tions may be different for lacZ and Pig-a, the kinetics of
mutation accumulation for both mutation targets is the
same once a mutation is ﬁxed. The similarity in doubling
dose is not unexpected given that both assays are
designed to measure gene mutation events, and therefore
involve the same mechanism of action. Interestingly, the
BaP doubling doses calculated here for the lacZ endpoint
also seem to increase with decreasing mitotic index of the
tissue. This is also expected, since replication is required
for mutation ﬁxation and tissues such as liver have previ-
ously been highlighted for low cell turnover [Mirsalis
et al., 1989].
Assuming that both the lacZ and Pig-a genes are neu-
tral (i.e., cells with lacZ or Pig-a muations are not
selected for or against in situ) [Cosentino and Heddle,
1996; Keller et al., 1999; Rosti, 2002; Lambert et al.,
2005], it might be predicted that their mutagenic efﬁcien-
cies should be the same; however, this does not appear to
be the case. Differences in the mutagenic efﬁciency and
Environmental and Molecular Mutagenesis. DOI 10.1002/em
TABLE II. Mutagenic Efﬁciency at the lacZ and Pig-a Loci
Endpoint
Mutagenic efﬁciency
(mutants per DNA adduct
in 10
8 nucleotides)
lacZ mutants in bone marrow 137 3 10
26
mutant Pig-a phenotypes in RET 5.47 3 10
26
TABLE I. BaP Doubling Doses Calculated For lacZ Mutant
Frequency, Mutant Pig-a Phenotypes and Micronucleus
Frequency
Endpoint Tissue
BaP doubling
dose (mg BaP/kg
body weight/day)
Standard
deviation
lacZ mutant
frequency
Bone marrow 0.458 0.249
Small intestine 2.12 59.7
Glandular stomach 1.28 1.57
Liver 2.17 0.581
Mutant Pig-a
phenotypes
RET 0.0856
a 0.106
RBC 0.346 0.272
Micronucleus
frequency
RET 21.7 0.29
RBC 16.8 0.0882
aCalculated using the spontaneous frequency of RET
CD24- from subse-
quent Muta
TM Mouse analyses performed using the newer immunomag-
netic scoring procedure (0.28 6 0.23 3 10
26). Doubling dose for this
endpoint could not be calculated using the method employed here since
no RET
CD242 were detected in unexposed animals.
Benzo[a]pyrene-inducedPig-a andlacZMutations 761the (related) magnitude of response between the two
mutation endpoints may be explained by several factors.
First and foremost, the discrepancy reﬂects the fact that
the population of bone marrow cells evaluated for lacZ
mutants differs from the population of cells evaluated for
Pig-a mutations. Since we could not measure adducts
directly in blood cells, for the purposes of the efﬁciency
calculation, we have assumed that all bone marrow cells
are capable of becoming RETs and RBCs. However, it is
well known that bone marrow is composed of many dif-
ferent stem cell populations, only a fraction of which are
hematopoietic stem cells (HSC), and, only a fraction of
these HSC are committed to the erythrocyte population.
The remainder of the HSCs are either destined to become
lymphoid progenitor cells (i.e., lymphocytes or natural
killer cells, etc.), or other myeloid-based blood cells (e.g.,
mast cells, macrophages, thrombocytes). Although mea-
surement of the proportions of cell types in the bone mar-
row that are committed to becoming RETs would prove
challenging, this information would permit a better esti-
mate of mutagenic efﬁciency for the Pig-a endpoint. It is
also important to note that DNA adducts were measured
in the whole genome, whereas lacZ mutants and mutant
Pig-a phenotypes are only measured at a speciﬁc locus
and there may be some variability in adduct levels
between the measured locus compared to the whole
genome.
It is important to note that the BaP doubling dose for
mutant Pig-a phenotypes in RETs (Table I) was calcu-
lated using the spontaneous frequency of RET
CD242 from
other analyses performed using the newer high throughput
scoring procedure [data not shown, method adapted for
mice from Dertinger et al. (2011)]. The BaP doubling
dose for the Pig-a endpoint in RET could not be calcu-
lated using the scoring method used for this study since
no RET
CD242 were detected in unexposed control animals
in this study, and a measurable level of background mu-
tant Pig-a phenotypes is required to calculate doubling
dose (see Eq. 1). This newer scoring method employs cell
separation by paramagnetic particles to dramatically
increase the number of cells scored, thus resulting in
more accurate measurements of spontaneous frequency of
RET
CD242.
Although the doubling dose values did not reveal any
signiﬁcant difference in the sensitivity of the two loci to
BaP, there are marked differences in the absolute values
of the mutant and phenotypic frequencies for the lacZ and
Pig-a loci, respectively. The high MF at the lacZ locus
relative to the Pig-a locus is analogous to the ﬁndings of
Skopek et. al. [1996] in their comparison of hprt and lacI.
The background mutation frequency in the lacI transgene
of BigBlue
TM rat was found to be approximately an order
of magnitude higher than that of hprt [Skopek et al.,
1996]. Here, we note a difference between the lacZ MF
and the mutant Pig-a phenotype frequency of two orders
of magnitude for spontaneous, and greater than one order
of magnitude for induced frequency (mean 5 24).
It should also be noted that older animals, such as those
used in this study, are known to have a higher frequency
of spontaneous mutations in lacZ, and other reporter
genes; however, we have no reason to expect that the sen-
sitivity of the mutation assays will be impaired. More-
over, the OECD guideline for TGR assays (no. 488) was
not available at the time that the animal work was carried
out, and no guidelines regarding animal age were avail-
able. Future work of this nature should adhere to the
OECD guideline [OECD, 2011].
Another important consideration is the fact that the
Pig-a gene is subject to transcription-coupled repair in the
mouse, while the lacZ transgene is not transcribed [Lam-
bert et al., 2005]. This difference would presumably con-
tribute to a higher frequency of mutations at the lacZ
locus. There is also the possibility that a higher frequency
of silent mutations (i.e., mutations that have no effect on
protein function) occur in either one of the lacZ or Pig-a
loci, and this contributes to inaccuracy of the measured
mutant frequency. Other unknown factors, such as the
sequence context and genomic location, may also contrib-
ute to the higher mutagenic efﬁciency observed for lacZ.
For example, Lichtenauer-Kaligis et al. (1993) have
shown that integration of hprt cDNA into different loca-
tions in the human TK6 genome results in differences in
mutability.
We have also integrated measurements of chromosome
damage into this 28-day repeat dose study by measuring
the micronucleus frequency in RETs and NCEs. These
measurements were made 48 hr following the last expo-
sure in accordance with OECD guideline 474 [OECD,
1997]. Integration was quite simple since only a small
blood sample is required for the analysis, and it can be
obtained from a living animal (e.g., by saphenous or sub-
mandibular vein bleed). The same animals can then be
used for analysis of mutations and DNA adducts at three
days following the last treatment, thereby reducing the
total number of animals required for the study. Integration
of multiple endpoints into subchronic repeat dose studies
has been highlighted as a way to reduce animal numbers
in genetic toxicology studies [Pfuhler et al., 2009]. A
recent study showed that the micronucleus assay, comet
assay, and Pig-a assay can be integrated into a 28-day
repeat dose study in rats [Shutsky et al., 2010], and meas-
urements of micronucleus frequency have been success-
fully carried out alongside the Pig-a assay in a 28-day
subchronic rat study [Dertinger et al., 2010].
In contrast to the gene mutation endpoints, the dose-
response kinetics of micronucleus formation were quite
different; the BaP doubling dose calculated for micronu-
cleus formation in RETs is approximately 10-fold higher
than those for the Pig-a and lacZ mutation endpoints.
This observation is consistent with the current understand-
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mutation formation. Neutral gene mutations have no
selective advantage or disadvantage, and hence, cells con-
taining new neutral mutations can accumulate over time
during continuous treatment of the exposed tissue. In con-
trast, micronuclei measured in RETs are formed during
mitosis and cannot accumulate with multiple cell divi-
sions since the MN-RET (i.e., polychromatic erythrocytes)
are expected to mature and enter the population of red
blood cells (i.e., NCEs).
In this study, we used the standard OECD TGR assay
testing regime of 28 1 3 days (i.e., 28 day exposure pe-
riod 1 3 day sampling time) since this is the minimum
time necessary for detection of mutations in the lacZ gene
[Thybaud et al., 2003; OECD, 2011]. We observed signif-
icant dose-dependent increases in BaP-induced Pig-a mu-
tant RET
CD242 and RBC
CD242 phenotypes and lacZ
mutants (Figs. 2 and 3, respectively). At the three day
sampling time, however, a higher proportion of mutant
Pig-a phenotypes is observed in the RET population (ver-
sus RBC). This has been shown previously, and is due to
the time required for the turnover of RETs into RBCs. In
mice, the maximum RET response is reached after
2 weeks; whereas, the maximum RBC response is reached
only after four weeks [Bhalli et al., 2011a]. The relatively
higher response observed in RETs may also be due to the
reduced lifespan of GPI-deﬁcient RBC due to their sus-
ceptibility to complement-mediated lysis [Tremml et al.,
1999]. Likely for these same reasons, we also observed a
higher mutagenic efﬁciency in RETs versus RBCs (Table
II). Although the sampling time of 3 days post-exposure
may not be optimal for the maximum Pig-a response, it is
sufﬁcient to observe dose-related effects and, importantly,
is compatible with integration into a TGR assay.
It is also possible that the 2813s a m p l i n gr e g i m ei sn o t
ideal for measuring DNA adducts; however, it is known that
adducts formed by BaP are relatively persistent following
acute dosing [Stowers and Anderson, 1985]. We are not
aware of previously published information on the kinetics of
formation and elimination of BPDE DNA adducts following
a 28-day subchronic repeat dose study in the mouse, how-
ever, studies by Poirier et al. conducted in rats may help
shed some light on murine DNA adduct kinetics. In Poirier
et al. [1982], Wistar-Furth rats were fed 2-acetylaminoﬂuor-
ene for 28-days and the kinetics of hepatic DNA adduct for-
mation and elimination were measured. Adduct levels
reached a plateau at approximately two weeks, and once
treatment stopped, adduct levels began to decrease. How-
ever, at three-days post-treatment greater than 90% of
adducts still remained [Poirier et al., 1982]. Based on this in-
formation, and the fact that the measured levels of BaP-
DNA adducts showed dose-dependency and strong correla-
tion with lacZ mutant frequency, it is safe to say that the
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the adduct levels measured at 72-hr post-exposure were a
sufﬁciently accurate representation of BaP internal dose.
Nevertheless, it should be acknowledged that the level of
BPDE adducts observed in a tissue at any given time
depends on the balance between the metabolic conversion of
BaP to BPDE (via phase I metabolism), detoxiﬁcation (via
phase II metabolism), the rate of adduct repair, and the cell
turnover rate. Therefore, although is seems plausible that the
DNA adduct levels on day 28 were slightly higher than those
at three days post-treatment, the sampling time required for
evaluation of lacZ mutant frequency did not permit assess-
ment of adduct frequency immediately following administra-
tion of the ﬁnal dose. It may be prudent to investigate the
kinetics of adduct loss following subchronic oral BaP expo-
sures in order to validate the efﬁcacy of simultaneous meas-
urements of numerous endpoints in the same animals.
A major hurdle in the validation of the Pig-a assay has
been conﬁrmation of the mutational basis for the observed
phenotypes (i.e., GPI-anchor deﬁciency); however, sequenc-
ing of Pig-a mutant blood cells is not possible since RBCs
lack nuclear DNA. Nevertheless, Pig-a mutations have been
conﬁrmed in GPI-anchor deﬁcient rat splenic T-cells [Miura
et al., 2008; Miura et al., 2011], and in patients with the
GPI-anchor deﬁciency disorder, paroxysmal nocturnal
hemoglobinurea (PNH) [Nishimura et al., 1999]. Compel-
ling evidence for the mutational origin of GPI-anchor deﬁ-
cient phenotypes in the Pig-a assay was most recently pre-
sented by Kimoto et al (2011). In that study, cDNA from
CD24-negative murine bone marrow cells was sequenced,
and it was shown that mutations in Pig-a are present when
CD24 is lacking [Kimoto et al., 2011]. Evidence of a simi-
lar doubling dose for the Pig-a locus and the more com-
monly employed lacZ locus provides further evidence for
the mutational origin of GPI-anchor deﬁciencies observed
in RBCs and RETs in the Pig-a assay, since the result
implies a similar mechanism of action.
In summary, we have demonstrated that multiple end-
points can be incorporated into a 28-day subchronic
mouse toxicity study, and the results obtained support the
validation of the Pig-a assay by showing that the assay
yields comparable responses (i.e., doubling dose) to the
commonly used and validated transgenic rodent mutation
assay, thus providing further support regarding its utility
as an in vivo somatic gene mutation assay. Although dif-
ferences in mutagenic efﬁciency were observed between
the two gene targets, we hypothesize that the differences
are likely due to difﬁculties in assessing adduct frequency
in the target cell populations, and differences in repair
capacity across loci, rather than differences in the rate of
conversion of adducts into mutations.
Future studies should aim to further investigate the
responsiveness of GPI-anchor deﬁcient cells in the Pig-a
assay relative to more established in vivo genetic toxicity
endpoints such as lacZ, including investigations of the
low dose region of the dose-response function. Moreover,
28-day repeat dose studies that test additional classes of
Environmental and Molecular Mutagenesis. DOI 10.1002/em
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time-course studies to examine the persistence of mutant
Pig-a phenotypes will provide further insight into the util-
ity of the assay, and will be important steps in the valida-
tion of the Pig-a endpoint as a useful and effective in
vivo somatic gene mutation assay.
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